102 related articles for article (PubMed ID: 19995756)
1. What have we learnt from targeted anti-TNF therapy?
Feldmann M; Williams RO; Paleolog E
Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i97-99. PubMed ID: 19995756
[TBL] [Abstract][Full Text] [Related]
2. Embracing novel cytokines in RA - complexity grows as does opportunity!
Hueber AJ; Asquith DL; McInnes IB; Miller AM
Best Pract Res Clin Rheumatol; 2010 Aug; 24(4):479-87. PubMed ID: 20732646
[TBL] [Abstract][Full Text] [Related]
3. Anti-TNFalpha therapy of rheumatoid arthritis: what can we learn about chronic disease?
Feldmann M; Brennan FM; Paleolog E; Cope A; Taylor P; Williams R; Woody J; Maini RN
Novartis Found Symp; 2004; 256():53-69; discussion 69-73, 106-11, 266-9. PubMed ID: 15027483
[TBL] [Abstract][Full Text] [Related]
4. The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis.
Feldmann M; Brennan FM; Williams RO; Woody JN; Maini RN
Best Pract Res Clin Rheumatol; 2004 Feb; 18(1):59-80. PubMed ID: 15123038
[TBL] [Abstract][Full Text] [Related]
5. Recapitulation of the round-table discussion--assessing the role of anti-tumour necrosis factor therapy in the treatment of rheumatoid arthritis.
Furst DE; Keystone E; Maini RN; Smolen JS
Rheumatology (Oxford); 1999 Nov; 38 Suppl 2():50-3. PubMed ID: 10646494
[TBL] [Abstract][Full Text] [Related]
6. [Anti-TNF-alpha therapy as a new option in treatment of rheumatoid arthritis?].
Leeb BF; Sautner J
Wien Med Wochenschr; 1999; 149(19-20):554-7. PubMed ID: 10637966
[TBL] [Abstract][Full Text] [Related]
7. TNF inhibitors - new and old agents for rheumatoid arthritis.
Simsek I
Bull NYU Hosp Jt Dis; 2010; 68(3):204-10. PubMed ID: 20969553
[TBL] [Abstract][Full Text] [Related]
8. Cytokine expression and networks in rheumatoid arthritis: rationale for anti-TNF alpha antibody therapy and its mechanism of action.
Feldmann M; Brennan FM; Williams RO; Elliott MJ; Maini RN
J Inflamm; 1995-1996; 47(1-2):90-6. PubMed ID: 8913935
[TBL] [Abstract][Full Text] [Related]
9. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis.
Charles P; Elliott MJ; Davis D; Potter A; Kalden JR; Antoni C; Breedveld FC; Smolen JS; Eberl G; deWoody K; Feldmann M; Maini RN
J Immunol; 1999 Aug; 163(3):1521-8. PubMed ID: 10415055
[TBL] [Abstract][Full Text] [Related]
10. TNF alpha as a therapeutic target in rheumatoid arthritis.
Feldmann M; Brennan FM; Elliott M; Katsikis P; Maini RN
Circ Shock; 1994 Aug; 43(4):179-84. PubMed ID: 7895323
[TBL] [Abstract][Full Text] [Related]
11. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis.
Salliot C; Finckh A; Katchamart W; Lu Y; Sun Y; Bombardier C; Keystone E
Ann Rheum Dis; 2011 Feb; 70(2):266-71. PubMed ID: 21097801
[TBL] [Abstract][Full Text] [Related]
12. Immunological therapies for rheumatoid arthritis.
Edwards CJ
Br Med Bull; 2005; 73-74():71-82. PubMed ID: 16174791
[TBL] [Abstract][Full Text] [Related]
13. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
14. Emerging biologic drugs for the treatment of rheumatoid arthritis.
Puppo F; Murdaca G; Ghio M; Indiveri F
Autoimmun Rev; 2005 Nov; 4(8):537-41. PubMed ID: 16214092
[TBL] [Abstract][Full Text] [Related]
15. Rheumatoid arthritis: choice of antirheumatic treatment. Methotrexate first.
Prescrire Int; 2010 Feb; 19(105):30-4. PubMed ID: 20455343
[TBL] [Abstract][Full Text] [Related]
16. Novel approaches for the treatment of rheumatoid arthritis: lessons from the evaluation of synovial biomarkers in clinical trials.
Gerlag DM; Tak PP
Best Pract Res Clin Rheumatol; 2008 Apr; 22(2):311-23. PubMed ID: 18455687
[TBL] [Abstract][Full Text] [Related]
17. [Biopharmaceuticals in the treatment of rheumatoid arthritis].
Baslund B; Bendtzen K
Ugeskr Laeger; 2008 Jun; 170(24):2108-10. PubMed ID: 18572481
[TBL] [Abstract][Full Text] [Related]
18. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy.
Rosner I; Haddad A; Boulman N; Feld J; Avshovich N; Slobodin G; Rozenbaum M
Rheumatology (Oxford); 2007 Sep; 46(9):1508; author reply 1508-9. PubMed ID: 17684027
[No Abstract] [Full Text] [Related]
19. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis.
Catrina AI; af Klint E; Ernestam S; Catrina SB; Makrygiannakis D; Botusan IR; Klareskog L; Ulfgren AK
Arthritis Rheum; 2006 Jan; 54(1):76-81. PubMed ID: 16385498
[TBL] [Abstract][Full Text] [Related]
20. Anti-TNF therapy, from rationale to standard of care: what lessons has it taught us?
Feldmann M; Maini RN
J Immunol; 2010 Jul; 185(2):791-4. PubMed ID: 20601610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
